Recruiting
Phase 2

Pain Medication

Sponsor:

Washington University School of Medicine

Code:

NCT07689162

Conditions

Pain, Postoperative

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Standard Bupivacaine

Liposomal Bupivacaine

Study Details

Brief summary:

The purpose of this study is to find out which pain medication is more effective in reducing pain after nose surgery (rhinoplasty). The investigators are looking to find the best treatment to reduce discomfort and improve the healing process for patients having nose surgery.

Conditions

Pain, Postoperative

Study ID

NCT07689162

Start date

Aug 1, 2026

Status verified date

Aug, 2026

Completion date

Jul, 2027

Anticipated

Primary completion date

Jun, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Adult patients (≥18 years) undergoing open rhinoplasty of any indication or complexity (e.g., primary, revision, functional, or cosmetic), including autologous grafting of any type (e.g., septal or costal cartilage) or cadaveric grafting.

Exclusion Criteria:

  • Chronic pain condition requiring ongoing or scheduled analgesic therapy, or any diagnosis associated with chronic pain (e.g., fibromyalgia, chronic headache/migraine, neuropathic pain, complex regional pain syndrome), long-term opioid use (≥3 months, any agent), allergy or contraindication to local anesthetics, acetaminophen, ibuprofen / NSAIDs, tramadol, ketamine, Medrol (methylprednisolone) dose pack
  • Concurrent non-nasal surgery planned

Study Design

Enrollment

45 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Liposomal Bupivacaine

Participants randomized to the experimental arm will receive bilateral supraorbital and infraorbital nerve blocks using liposomal bupivacaine at the end of surgery.

active comparator: Standard Bupivacaine

The control arm will receive standard bupivacaine nerve blocks using the same injection sites and volumes appropriate for safe regional anesthesia

Interventions

Standard Bupivacaine

Volume: 4 mL of 0.75% bupivacaine hydrochloride

Liposomal Bupivacaine

Volume: 1.5 mL of 0.75% bupivacaine hydrochloride and 2.5 mL of liposomal bupivacaine

Primary outcome measure

  • Cumulative opioid consumption [ Time Frame: First 72 hours postoperatively ]

Central Contacts and Locations

Central contacts

Matthew Wu, MD

314-362-0524mjwu@wustl.edu

Sara Kukuljan, BS, RN

314-362-7563kukuljas@wustl.edu

Locations

Washington University

Recruiting

St Louis, Missouri, United States, 63110

Contacts

Sara Kukuljan, BS, RN

314-362-7563kukuljas@wustl.edu

More Information

Sponsor

Washington University School of Medicine

Last update posted

Aug 18, 2026

Last verified

Aug, 2026

Keywords

  • Otolaryngology
  • Rhinoplasty
  • Bupivacaine
  • Liposomal Bupivacaine

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Washington University School of Medicine on 2026-08-18.